Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brimonidine Purite is a reformulated ophthalmic solution of brimonidine tartrate preserved with Purite, a stabilized oxychloro complex. It is a relatively selective alpha-2 adrenergic receptor agonist used topically to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The drug acts by reducing aqueous humor production and increasing uveoscleral outflow, resulting in decreased IOP. The Purite preservative was introduced to improve tolerability compared to older formulations using benzalkonium chloride, while maintaining efficacy. Brimonidine-Purite is available in 0.1% and 0.15% concentrations; both have been shown to be equally effective for IOP lowering and are well tolerated[5][6]. The main brand name for this formulation is Alphagan P.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brimonidine purite.